IP Library Granted Patent US 8,889,657
Granted Patent B2
US 8,889,657 · App. 13/599,819 · Granted Nov 18, 2014

Nanoparticle PEG modification with H-phosphonates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,889,657
App. No.
13/599,819
Granted
Nov 18, 2014
Kind
B2
Abstract

The present invention provides phosphonate conjugates and methods of preparing the phosphonate conjugates so as to allow, for example, improved methods and compounds for modifying the surface of a nanoparticle to increase in vivo circulation times and targeted delivery performance.

Claims (30)

1. A compound of the formula:

wherein

each L 1 , L 2 , L 3 and L 4 is independently selected from the group consisting of a bond and a linking group;

R 1 is selected from the group consisting of a nanoparticle, an attachment component, a targeting agent, a diagnostic agent, a stealth agent, and a tetrapodal presentation component;

each R 2 is independently selected from the group consisting of a stealth agent, C 1 -C 10 alkyl, a carboxylic acid or ester, a phosphonic acid or ester, a sulfonic acid or ester, and a hydroxy;

each R 3 and R 4 is independently selected from the group consisting of H, a nanoparticle, an attachment component, a targeting agent, a diagnostic agent, and a stealth agent, wherein at least one of R 3 or R 4 is other than H; and

n is an integer of from 0 to 2.

2. The compound of claim 1 , wherein at least one of L 1 , L 2 , L 3 , and L 4 is a hydrophilic, non-immunogenic, water soluble linking group.

3. The compound of claim 2 , wherein the hydrophilic, non-immunogenic, water soluble linking group is selected from the group consisting of polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polycarboxylate, polysaccharide and dextran.

4. The compound of claim 1 , wherein the targeting agent is an aptamer.

5. The compound of claim 1 , wherein the diagnostic agent is a radioactive agent, a fluorescent agent, or a contrast agent.

6. The compound of claim 1 , wherein the stealth agent is selected from the group consisting of a dendrimer, polyalkylene oxide, polyvinyl alcohol, polycarboxylate, a polysaccharide and hydroxyalkyl starch.

7. The compound of claim 6 , wherein the stealth agent is a polyalkylene oxide.

8. The compound of claim 7 , wherein the polyalkylene oxide is a polyethylene glycol (PEG) ranging from PEG 100 to PEG 10000 .

9. The compound of claim 6 , wherein the polyalkylene oxide is polyethylene glycol (PEG) selected from the group consisting of PEG 100 , PEG 500 , PEG 1000 , PEG 2000 , PEG 5000 and PEG 10000 .

10. The compound of claim 1 , wherein the stealth agent comprises at least two PEG molecules linked together with a linking group.

11. The compound of claim 1 , wherein R 1 is a tetrapodal presentation component having the formula:

wherein

each L 5 and L 6 is independently selected from the group consisting of a bond and a linking group; and

each R 5 and R 6 is independently selected from the group consisting of a targeting agent, a diagnostic agent, and a stealth agent.

12. The compound of claim 1 , wherein each of R 3 and R 4 is independently selected from the group consisting of a lipid and cholesterol.

13. The compound of claim 1 , wherein R 1 is a stealth agent; and each of R 3 and R 4 is an attachment component and independently selected from the group consisting of a lipid and cholesterol, wherein the attachment component is attached to a nanoparticle.

14. The compound of claim 13 , wherein the lipid is saturated or unsaturated C 10 -C 22 alkyl.

15. The compound of claim 14 , wherein n is 0.

16. The compound of claim 1 , wherein R 1 is an attachment component; and R 3 and R 4 are independently selected from the group consisting of a targeting agent, a diagnostic agent and a stealth agent.

17. The compound of claim 1 , wherein R 1 is a stealth agent selected from the group consisting of PEG 100 , PEG 500 , PEG 1000 , PEG 2000 , PEG 5000 and PEG 10000 .

18. The compound of claim 1 , wherein R 1 is an attachment component, and the attachment component is a phospholipid.

19. The compound of claim 18 , wherein the phospholipid has the formula:

wherein each of R 7 and R 8 is independently selected from the group consisting a saturated or unsaturated C 10-24 alkyl or alkanoyl group and a substituted saturated or unsaturated C 10-24 alkyl or alkanoyl group.

20. The compound of claim 1 , wherein each R 1 and R 2 is a stealth agent; each R 3 and R 4 is an attachment component independently selected from the group consisting of a lipid and cholesterol; and n is 1.

Assignments (3)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2014
From: ROGERS, THOMAS E.
To: MALLINCKRODT LLC
Reel/Frame 033905/0317 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →